» Articles » PMID: 35721940

Inhibition Mechanisms of (-)-Epigallocatechin-3-gallate and Genistein on Amyloid-beta 42 Peptide of Alzheimer's Disease Via Molecular Simulations

Overview
Journal ACS Omega
Specialty Chemistry
Date 2022 Jun 20
PMID 35721940
Authors
Affiliations
Soon will be listed here.
Abstract

The misfolding and self-assembly of amyloid-beta (Aβ) peptides are one of the most important factors contributing to Alzheimer's disease (AD). This study aims to reveal the inhibition mechanisms of (-)-epigallocatechin-3-gallate (EGCG) and genistein on the conformational changes of Aβ42 peptides by using molecular docking and molecular dynamics (MD) simulation. The results indicate that both EGCG and genistein have inhibitory effects on the conformational transition of Aβ42 peptide. EGCG and genistein reduce the ratio of β-sheet secondary structures of Aβ42 peptide while inducing random coil structures. In terms of hydrophobic interactions in the central hydrophobic core of Aβ42 peptide, the binding affinities of EGCG are significantly larger in comparison with that of genistein. Our findings illustrate the inhibition mechanisms of EGCG and genistein on the Aβ42 peptides and prove that EGCG is a very promising inhibitor in impeding the conformational change of Aβ42 peptide.

Citing Articles

Identification of Chlorogenic Acids from Leaves as Modulators of Prion Aggregation Using Affinity Selection-Mass Spectrometry.

Amorim M, Amaral-do-Nascimento M, Severino V, Silva J, Vieira T, de Moraes M ACS Omega. 2025; 10(3):2919-2930.

PMID: 39895746 PMC: 11780439. DOI: 10.1021/acsomega.4c09150.


Epigallocatechin 3-gallate-induced neuroprotection in neurodegenerative diseases: molecular mechanisms and clinical insights.

Islam M, Rauf A, Akter S, Akter H, Al-Imran M, Islam S Mol Cell Biochem. 2025; .

PMID: 39832108 DOI: 10.1007/s11010-025-05211-4.


Impact of Some Natural and Artificial Sweeteners Consumption on Different Hormonal Levels and Inflammatory Cytokines in Male Rats: In Vivo and In Silico Studies.

Mohammed D, Abdelgawad M, Ghoneim M, Alhossan A, Al-Serwi R, Farouk A ACS Omega. 2024; 9(28):30364-30380.

PMID: 39035958 PMC: 11256323. DOI: 10.1021/acsomega.4c01250.


Protein aggregation and neurodegenerative disease: Structural outlook for the novel therapeutics.

Arar S, Haque M, Kayed R Proteins. 2023; .

PMID: 37530227 PMC: 10834863. DOI: 10.1002/prot.26561.


Realization of Amyloid-like Aggregation as a Common Cause for Pathogenesis in Diseases.

Naskar S, Gour N Life (Basel). 2023; 13(7).

PMID: 37511898 PMC: 10381831. DOI: 10.3390/life13071523.


References
1.
Pettersen E, Goddard T, Huang C, Couch G, Greenblatt D, Meng E . UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem. 2004; 25(13):1605-12. DOI: 10.1002/jcc.20084. View

2.
Knopman D, Amieva H, Petersen R, Chetelat G, Holtzman D, Hyman B . Alzheimer disease. Nat Rev Dis Primers. 2021; 7(1):33. PMC: 8574196. DOI: 10.1038/s41572-021-00269-y. View

3.
Hardy J, Selkoe D . The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002; 297(5580):353-6. DOI: 10.1126/science.1072994. View

4.
Ren B, Liu Y, Zhang Y, Cai Y, Gong X, Chang Y . Genistein: A Dual Inhibitor of Both Amyloid β and Human Islet Amylin Peptides. ACS Chem Neurosci. 2018; 9(5):1215-1224. DOI: 10.1021/acschemneuro.8b00039. View

5.
Volkamer A, Kuhn D, Grombacher T, Rippmann F, Rarey M . Combining global and local measures for structure-based druggability predictions. J Chem Inf Model. 2011; 52(2):360-72. DOI: 10.1021/ci200454v. View